These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 8877027)

  • 1. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.
    Souillard A; Audran M; Bressolle F; Gareau R; Duvallet A; Chanal JL
    Br J Clin Pharmacol; 1996 Sep; 42(3):355-64. PubMed ID: 8877027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclists.
    Birkhoff WAJ; Heuberger JAAC; Post TE; Gal P; Stuurman FE; Burggraaf J; Cohen AF
    Physiol Rep; 2018 Dec; 6(24):e13924. PubMed ID: 30592183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.
    Krzyzanski W; Perez-Ruixo JJ; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):349-77. PubMed ID: 18551354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Immature Reticulocytes Aid the Indirect Detection of Microdose Recombinant Erythropoietin Use in Men and Women.
    Breenfeldt Andersen A; Bejder J; Bonne TC; Graae J; Seier S; Nordsborg NB
    Med Sci Sports Exerc; 2023 Sep; 55(9):1695-1705. PubMed ID: 37095637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration study of recombinant erythropoietin on the carriers of variant c.577del in EPO gene.
    He S; Liu X; Song H; Zhou X
    Drug Test Anal; 2023; 15(11-12):1410-1416. PubMed ID: 37644676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced analysis of equine plasma for the presence of recombinant human erythropoietin - Implementation of an improved workflow.
    Richards S; Palmer D; Cawley A; Wainscott M; Keledjian J
    Drug Test Anal; 2024 Aug; ():. PubMed ID: 39097987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing EPO stability in urine and comparing recombinant EPO detectability in matched urine, venous serum, and capillary serum following a controlled epoetin alfa administration.
    Miller GD; Goodrum JM; Crouch AK; Eichner D
    Drug Test Anal; 2024 May; ():. PubMed ID: 38785206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of DNA concentration in urine and dried blood samples to detect the c.577 deletion within the EPO gene.
    Leuenberger N; Jan N; Kuuranne T; Castella V
    Drug Test Anal; 2024 Jan; ():. PubMed ID: 38247130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
    Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
    Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO
    Reynaldo G; Rodríguez L; Menéndez R; Solazábal J; Amaro D; de Los A Becquer M; Colom Y; Gil H; Polo JC; Castañeda G; Jiménez-Vélez B; Duconge J; Fernández-Sánchez EM
    J Pharm Pharmacogn Res; 2018; 6(3):179-190. PubMed ID: 30739984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.
    Kim S; Hong T; Ko JW; Huh W; Kim JR
    BioDrugs; 2019 Feb; 33(1):101-112. PubMed ID: 30506495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon
    Yoon S; Rhee SJ; Heo SJ; Oh TY; Yoon SH; Cho JY; Lee S; Yu KS
    Drug Des Devel Ther; 2017; 11():3127-3135. PubMed ID: 29138535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.
    Doshi S; Krzyzanski W; Yue S; Elliott S; Chow A; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2013 Dec; 52(12):1063-83. PubMed ID: 23912564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration.
    Schirm S; Engel C; Loeffler M; Scholz M
    PLoS One; 2013; 8(6):e65630. PubMed ID: 23755260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.
    Gaudard A; Varlet-Marie E; Audran M; Gomeni R; Bressolle F
    Clin Drug Investig; 2003; 23(3):167-79. PubMed ID: 23340923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.
    Heuberger JA; Cohen Tervaert JM; Schepers FM; Vliegenthart AD; Rotmans JI; Daniels JM; Burggraaf J; Cohen AF
    Br J Clin Pharmacol; 2013 Jun; 75(6):1406-21. PubMed ID: 23216370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intermittent hypoxia on hematological parameters after recombinant human erythropoietin administration.
    Sanchis-Gomar F; Martinez-Bello VE; Domenech E; Nascimento AL; Pallardo FV; Gomez-Cabrera MC; Vina J
    Eur J Appl Physiol; 2009 Nov; 107(4):429-36. PubMed ID: 19669157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.
    Elliott S
    Br J Pharmacol; 2008 Jun; 154(3):529-41. PubMed ID: 18362898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reticulocytes in sports medicine.
    Banfi G
    Sports Med; 2008; 38(3):187-211. PubMed ID: 18278982
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.